Theravance Biopharma, Inc. filings document operating results, material events, governance matters, and portfolio disclosures for a Cayman Islands biopharmaceutical issuer. Form 8-K reports furnish quarterly and annual financial updates, YUPELRI collaboration revenue, business updates, Regulation FD materials, and financial-condition disclosures tied to the company’s therapeutics business.
The filing record also covers product and intellectual-property matters, including a Hatch-Waxman settlement resolving ANDA patent litigation involving YUPELRI® (revefenacin) inhalation solution. Other disclosures address the ampreloxetine Phase 3 CYPRESS outcome, costs associated with organizational restructuring and program wind-down activities, annual general meeting voting matters, director elections, and proxy governance.
Theravance Biopharma, Inc. (TBPH) reported an insider equity transaction by a senior executive. The reporting person, identified as an officer with the title "SVP, DEV & HEAD OF IRE OFFICE," filed a Form 4 for activity dated 11/20/2025.
The filing shows that 6,989 ordinary shares were withheld and disposed of at a price of $17.90 per share in a transaction coded "F," which indicates shares were withheld to cover tax obligations from vesting restricted stock units. After this tax withholding, the reporting person beneficially owns 201,012 ordinary shares, held directly.
An explanation clarifies that the share withholding was with the issuer and did not involve an open market transaction. The form is filed for one reporting person and is signed by an attorney-in-fact on 11/24/2025.
Theravance Biopharma, Inc. officer reports tax-related share withholding. A senior vice president who is also general counsel and secretary reported that on 11/20/2025, 19,024 ordinary shares were withheld at a price of $17.9 per share. These shares were retained by the company to cover tax obligations from the vesting of previously granted restricted stock units, and the event did not involve any open market transactions. After this withholding, the officer beneficially owns 355,282 ordinary shares directly.
Theravance Biopharma, Inc. reported an insider equity transaction by a senior officer. On 11/20/2025, 9,060 ordinary shares were withheld at $17.90 per share to cover tax obligations from the vesting of previously granted restricted stock units. The explanation states that this share withholding was with the issuer and did not involve any open market transaction. Following this tax-related transaction, the officer directly beneficially owns 308,762 ordinary shares of Theravance Biopharma.
Theravance Biopharma, Inc. (TBPH) reported insider share movements by its Chief Executive Officer, who is also a director. On 11/19/2025, the reporting person made a gift of 9,900 ordinary shares and transferred the same number of shares into a custodial account under the Uniform Transfers to Minors Act, where the person serves as custodian and disclaims beneficial ownership of the grandchildren's shares. After this, 23,400 shares were held indirectly in the custodial account.
On 11/20/2025, 56,817 ordinary shares were withheld at a price of $17.9 per share to satisfy tax obligations from vesting restricted stock units in a transaction with the issuer. Following these transactions, the reporting person held 1,651,069 ordinary shares directly and 92,567 ordinary shares indirectly through a trust, in addition to the UTMA custodial holdings.
Theravance Biopharma (TBPH) filed a Form 4/A amending an insider transaction by a director under a Rule 10b5-1 plan adopted March 14, 2024. On 11/11/2025, the director sold 15,500 shares at $18.50 and 15,500 shares at $17. The filing also shows the exercise of 14,000 options at $10.15 and a same‑day sale of those 14,000 shares at $18.50. Following these transactions, beneficial ownership was 60,204 shares. The amendment corrects an earlier administrative error that had overstated one sale as 29,500 shares at $18.50.
Theravance Biopharma (TBPH) director reported insider transactions on Form 4. On 11/11/2025, the reporting person sold 29,500 Ordinary Shares at $18.5, 15,500 shares at $17, and sold 14,000 shares at $18.5 after exercising options at $10.15. These trades were made under a Rule 10b5-1 trading plan adopted on March 14, 2024.
Following the transactions, the reporting person beneficially owned 46,204 Ordinary Shares directly and held 107,878 derivative securities. The 14,000-share option was fully vested and exercisable per its original vesting terms.
Theravance Biopharma reported Q3 2025 results. Revenue was $19.99 million, driven by the Viatris collaboration on YUPELRI. The quarter produced net income of $3.6 million (basic and diluted EPS $0.07) versus a loss a year ago.
For the first nine months, revenue reached $61.6 million and net income was $44.9 million (diluted EPS $0.88), reflecting a $75.1 million gain from the $225 million sale of future TRELEGY royalties and a $50 million milestone receipt tied to 2024 TRELEGY sales. Core operations remained loss-making with a $23.6 million loss from operations year to date.
Cash, cash equivalents and restricted cash rose to $175.6 million as of September 30, 2025. YUPELRI net sales recorded by Viatris were $71.4 million in Q3 (Theravance’s implied 35% share: $25.0 million), and a $7.5 million China approval milestone was recognized year to date. Several YUPELRI patent suits were settled, with licensed generic US entry no earlier than April 23, 2039; one case remains pending.
Theravance Biopharma (TBPH) furnished an 8-K announcing a press release and conference call covering financial results for the quarter ended September 30, 2025, along with a business update.
The materials include a press release (Exhibit 99.1) and a slide deck titled Third Quarter 2025 Financial Results and Business Update (Exhibit 99.2). The information in Item 2.02 and Item 9.01, including Exhibits 99.1 and 99.2, is being furnished and shall not be deemed filed under the Exchange Act.
Theravance Biopharma, Inc. reported that it has completed enrollment in the open-label portion of its pivotal Phase 3 CYPRESS study. This trial is evaluating a treatment in patients with symptomatic neurogenic orthostatic hypotension caused by multiple system atrophy.
The company described the study as pivotal and noted that all information related to this milestone is provided in a press release furnished as an exhibit. That press release is supplied for informational purposes and is not deemed filed under securities laws.
Rick E. Winningham, identified as both a Director and the Chief Executive Officer of Theravance Biopharma, reported a Form 4 transaction dated 08/20/2025. The filing discloses that 15,394 ordinary shares were withheld to satisfy tax obligations arising from the vesting of previously granted restricted stock units; the withholding was executed with the issuer and did not involve an open market sale. The report shows 1,717,786 shares beneficially owned directly after the transaction, plus 13,500 shares held as custodian and 92,567 shares held by trust, all listed as indirect holdings. The stated price per share associated with the withheld shares is $13.39. The form was signed by an attorney-in-fact on 08/22/2025.